Xtant Bets on a Bigger Bag: Integrating Dilon's Sales Force While Trimming Guidance
Q2 2026 shows integration costs and amnio headwinds, but management points to a larger commercial footprint and new products.
XTNT · Earnings Call · 2026-08-11
A Quarter of Integration and a Guidance Trim
Xtant Medical's second quarter of 2026 was defined less by the top line and more by the orchestration of a deeper commercial transformation. Reported revenue of $23.0 million fell 35% year-over-year, and the company trimmed its full-year revenue outlook to $99–103 million from a prior $101–105 million. “We are building a solid, resilient foundation that we believe will support sustained, predictable and profitable growth in the future,” — Sean Browne, President and Chief Executive Officer · 2026-08-11 said CEO Sean Browne, signalling that the near-term pain is a deliberate down payment on scale. But the numbers tell a harsher story: the net loss widened to $9.4 million, adjusted EBITDA swung to a $2.7 million loss, and gross margin contracted to 57.9% from 68.6% a year ago. Total Revenue fell to $21M in the first quarter of 2026 and $23M in Q2, well below the $32–35M quarterly run-rate of late 2025. The guidance cut directly acknowledges the Amnio product headwinds and legacy DBM softness that management has repeatedly flagged.
HEMOBLAST: The Cost of a Bigger Bag
The headline story of the quarter is the integration of Dilon Technologies' 17 sales reps and 2 regional managers, plus the exclusive U.S. distribution rights to HEMOBLAST Bellows. The revenue recognition, however, lagged expectations: Scott Neils explained that “the $1.5 million of revenue that we recognized in the second quarter was accounted for primarily on a net basis as it was shipped directly to customer sites from the Dilon Technologies facility under Dilon's customer agreements.” — Scott Neils, Chief Financial Officer · 2026-08-11 Management had hoped to ship more through Xtant's own POs, which would have added $600–700K to reported revenue. Further, the training of these new reps consumed time that, in Sean's words, "played a role in our soft Q2 sales." Yet the company views this as a foundational investment. As Scott told analysts on the call,
we haven't backed off of our expectation around transactional volume, which would be over $1 million per month on a gross basis.
The Dilon addition is a clear sales force expansion play, aimed at cross-selling the entire Xtant bag into new hospital call points. Sean noted that the specialty reps are now "getting comfortable with our orthobiologics product lines," and that they will also "start getting touches to those other guys" among the 650 independent agent agreements.
New Products and Adjacent Markets
Amid the integration, Xtant launched Trivium Shaped in May, building on the Trivium composite allograft platform. Sean highlighted the product's early traction: “Surgeons tell us that these pre-shape formats reduce preparation time and support more predictable placement, and that feedback is translating directly into the sales momentum we are seeing since launch.” — Sean Browne, President and Chief Executive Officer · 2026-08-11 This, combined with CollagenX and OsteoFactor Pro, positions the company to move into chronic wound care and surgical repair—a combined TAM of roughly $6.5 billion, according to management. The hemostatic addition opens another $1 billion market. The keyword Trivium Shaped has been a rising theme across recent quarters, and the company's increased biologics growth ambitions hinge on these new offerings. However, the gross margin profile remains under pressure; the company booked a 57.9% margin this quarter, down from 68.6% last year, hurt by the cessation of Q-Code license revenue and excess inventory charges. Gross Margin fell to 57.9% in Q2, back to mid-2023 levels, after peaking at 69% in Q2 2025.
The Struggle Beneath the Surface
The recurring drag from the amnio line and legacy DBM products is not new. In the prior quarter, Sean conceded that "the amnio business... has been down more than we expected," and in March he noted that distributors would shift to Xtant-branded contracts over time. “More of those distributors will be using our contracts, and it will be actually [Xtant] brand.” — Sean Browne, President and Chief Executive Officer · 2026-03-31 That transition has been slower than hoped, and the second quarter showed little sign of a "green shoots" recovery. Meanwhile, the businesses to Companion Spine divestitures have reduced the hardware drag but also trimmed the easy growth. On the tape, the market has punished the story: the 90-day return is -32.3%, with a drawdown of -44% from the May 2026 peak of $0.58. Effective Net Cash fell to -$3M from a positive $25M a year ago, reflecting the Dilon exclusivity fee and operating losses. The company ended the quarter with $9.9M of cash and $23M of debt, with just $0.7M available on its revolver—a tight balance sheet that makes the execution of this "bigger bag" strategy all the more imperative. As Sean said, “we're just thrilled that we're getting some business, and we're hoping to pull through other contracts that go along with that.” — Sean Browne, President and Chief Executive Officer · 2026-08-11 This optimism, however, is a distant echo of the November 2025 planning, when Sean explained the sales force rebuild as a deliberate choice: “we've now been replacing a lot of those spots in areas that make more sense.” — Sean E. Browne, President and Chief Executive Officer · 2025-11-11